Please login to the form below

Not currently logged in
Email:
Password:

Osmotica Pharmaceuticals appoints new vice president

Samer Kaba joins the firm

Osmotica Pharmaceuticals has appointed Samer Kaba as vice president and head of global clinical development and medical affairs.

Kaba brings experience in developing pharmaceutical products for neurology, analgesia, and autoimmune diseases and has spent 15 years in the pharmaceutical industry in global clinical development programmes from early to late stage development and submission of NDAs and global marketing authorisations.

Praveen Tyle, president and CEO of Osmotica, said: “We are very pleased to have Samer as part of our senior leadership team at such an exciting time as he will be instrumental in further progressing Osmotica's recent achievements in our two lead CNS product candidates – Ontinua ER and Osmolex ER.

“Dr. Kaba's experience in multiple sclerosis will also be instrumental in discussions with FDA for the approval of Ontinua ER, which was accepted for filing by the FDA recently.”

8th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...
BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....

Infographics